MiMedx
-
Recon
MiMedx to Webcast Its Analyst Day on October 13, 2015
MARIETTA, Ga., Sept. 15, 2015 /PRNewswire/ — MiMedx Group, Inc. MDXG, +1.45%the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes…
Read More » -
Uncategorized
MiMedx Corrects A Second Inaccurate MTF Press Release
MARIETTA, Ga., Sept. 2, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected…
Read More » -
Hospitals
MTF Receives Favorable Ruling from the Patent Trial and Appeal Board in Patent Dispute with MiMedx
EDISON, N.J., Aug. 25, 2015 /PRNewswire/ — The Musculoskeletal Transplant Foundation (MTF) announced today the Patent Trial and Appeal Board (“PTAB”) has ruled…
Read More » -
Financial
MiMedx Updates Second Quarter Information
MARIETTA, Ga., Aug. 6, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected…
Read More » -
Biologics
MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference
MARIETTA, Ga., Aug. 3, 2015 /PRNewswire/ — MiMedx Group, Inc. MDXG, -4.85% the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes…
Read More » -
Financial
MiMedx Reports Record First Quarter 2015 Revenue of $40.8 Million
MARIETTA, Ga., April 13, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes…
Read More » -
Biologics
MiMedx To Present At The 14th Annual Needham Healthcare Conference
MARIETTA, Ga., April 1, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes…
Read More » -
Biologics
MiMedx Group reports record revenue of $118.2 million for full year 2014
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and…
Read More » -
Biologics
Organogenesis blasts back after MiMedx bails on lawsuit
February 5, 2015 by Brad Perriello Organogenesis blasts back after MiMedx says it’s bailing out of a tortious interference lawsuit.…
Read More » -
Biologics
Mimedx receives subpoena from Office of Inspector General, HHS
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and…
Read More » -
Hospitals
MiMedx pleased with FDA Draft Guidance on Minimal Manipulation of HCT/Ps
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and…
Read More » -
Financial
MiMedx Group revenue up 108% in third quarter 2014
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and…
Read More » -
Biologics
MiMedx announces record revenue results for Q3 2014, issues updated guidance
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and…
Read More » -
Biologics
MiMedx Announces Revised Local Coverage Determination From Medicare Contractor That Includes EpiFix®
MARIETTA, Ga., July 14, 2014 /PRNewswire/ — MiMedx Group, Inc. (MDXG), an integrated developer, processor and marketer of patent protected…
Read More » -
Medtronic to Market MiMedx Group PURION Processed Allograft Products
MiMedx Group entered into a distribution agreement with Medtronic and SpinalGraft Technologies, a subsidiary of Medtronic. MiMedx’s PURION processed allograft…
Read More »